Medicines Co. (MDCO) – Press Releases
-
Attralus Therapeutics Appoints Mark Timney as CEO and Expands Leadership Team with New Executives
-
Blade Therapeutics Appoints Accomplished Biopharmaceutical Executive, Mark Timney, as Chairman of the Board
-
The Medicines Company Announces Effective Date Of Make-Whole Fundamental Change Relating To Its 2.50% Convertible Senior Notes Due 2022, 2.75% Convertible Senior Notes due 2023 and 3.50% Convertible S
-
Novartis completes tender offer for all outstanding shares of The Medicines Company
-
NexPoint Residential Trust and Meritor Set to Join S&P SmallCap 600
-
Novartis tender offer for The Medicines Company commences
-
The Medicines Company Enters Into Definitive Agreement to be Acquired by Novartis AG for $9.7 Billion
-
Novartis to acquire The Medicines Company for USD 9.7 bn, adding inclisiran, a potentially transformational investigational cholesterol-lowering therapy to address leading global cause of death
-
The Medicines Company Announces that the ORION-9 Study of Inclisiran in HeFH Patients Showed Durable and Potent LDL-C Lowering with Twice-Yearly Dosing
-
The Medicines Company Announces that the ORION-10 Study of Inclisiran in ASCVD Patients Showed Durable and Potent Lowering of LDL-C with Twice-Yearly Dosing
-
The Medicines Company to Present Inclisiran Data from ORION-9 and ORION-10 Pivotal Phase 3 Clinical Studies at American Heart Association Scientific Sessions 2019
-
The Medicines Company Reports Third-Quarter 2019 Financial Results and Achievement of Major Milestones for Inclisiran
-
The Medicines Company to Announce Third Quarter 2019 Financial Results on October 30
-
Oncolytics Biotech(R) Appoints Experienced Financial and Strategic Leader Leonard Kruimer to Board of Directors
-
The Medicines Company to Participate in the Chardan 3rd Annual Genetic Medicines Conference
-
The Medicines Company Announces Positive Topline Results for ORION-10 Phase 3 Study of Inclisiran in ASCVD Patients
-
The Medicines Company Announces Positive Topline Results for ORION-9 Phase 3 Study of Inclisiran in Heterozygous Familial Hypercholesterolemia Patients
-
The Medicines Company Presents Results from ORION-11, First Phase 3 Trial of Inclisiran, Showing Durable and Potent Lowering of LDL-C with Twice-Yearly Dosing
-
The Medicines Company Announces Positive Topline Results from First Pivotal Phase 3 Trial of Inclisiran
-
The Medicines Company Reports Second-Quarter 2019 Financial Results and Updates Clinical Development Program
-
The Medicines Company to Announce Second Quarter 2019 Financial Results on July 24
-
The Medicines Company Announces Pricing of Public Offering of Common Stock
-
The Medicines Company Announces Launch of Public Offering of Common Stock
-
The Medicines Company Presents Clinical Data Analyses for Inclisiran at 87th European Atherosclerosis Society Congress
-
New Long-Term Data Show that Twice-a-Year Dosing with Inclisiran Results in Persistent Lowering of LDL Cholesterol with No Material Safety Observations Out to Three Years
-
The Medicines Company to Host Investor Conference Call and Webcast During National Lipid Association’s 2019 Scientific Sessions
-
The Medicines Company to Participate in the Bank of America Merrill Lynch 2019 Healthcare Conference
-
The Medicines Company Reports First-Quarter 2019 Financial Results and Significant Progress with the Inclisiran Clinical Development Program
-
The Medicines Company to Announce First Quarter 2019 Financial Results on April 25
-
The Medicines Company Reports Fourth-Quarter and Full Year 2018 Business and Financial Results
-
The Medicines Company Announces Upcoming Investor Conference Presentations
-
The Medicines Company to Announce Fourth-Quarter and Full-Year 2018 Financial Results on February 27
-
The Medicines Company Announces 5th Review of Un-blinded Data and Recommendation by Independent Data Monitoring Committee to Continue Inclisiran Phase 3 Trials
-
The Medicines Company Prices $150 Million of Convertible Notes
-
The Medicines Company Announces Intention to Offer $150 Million of Convertible Notes
-
The Medicines Company Appoints Mark Timney as Chief Executive Officer
-
Company Profile for The Medicines Company
-
The Medicines Company Reports Third-Quarter 2018 Results
-
The Medicines Company to Announce Third-Quarter 2018 Financial Results on November 8
-
Investor Expectations to Drive Momentum within Fossil Group, The Medicines, BWX Technologies, PVH, Group 1 Automotive, and Assurant — Discovering Underlying Factors of Influence
-
The Medicines Company Announces Recommendation by Independent Data Monitoring Committee to Continue Inclisiran Phase III Trials Following Fourth Review of Unblinded Data
-
The Medicines Company Reports Second-Quarter 2018 Results
-
The Medicines Company to Announce Second-Quarter 2018 Financial Results on August 1
-
The Medicines Company Announces Recommendation by Independent Data Monitoring Committee to Continue Inclisiran Phase III Trials Following [Third] Review of Unblinded Data
-
New Data Presented at the American Diabetes Association 78th Scientific Sessions® Reinforce the Potential of The Medicines Company’s inclisiran in Patients with Diabetes
-
The Medicines Company Announces Inclisiran Data Showing Significant Reductions in Potentially Harmful Subtypes of Bad Cholesterol (Atherogenic Lipoproteins) Linked to Heart Attack and Stroke
-
The Medicines Company Presents New Data at the National Lipid Association Scientific Sessions
-
The Medicines Company Reports First-Quarter 2018 Results
-
The Medicines Company to Announce First-Quarter 2018 Financial Results on April 25
-
The Medicines Company Announces Chief Financial Officer Transition
Back to MDCO Stock Lookup
